3. iPad Instructions

4. iPad Instructions

5. Polling Question

6. Polling Question

7. Polling Question

8. Polling Question

9. Polling Question

11. Poll Question

12. Rome IV: What Has Changed?

13. Rome IV IBS Subtypes

14. IBS Pathophysiology

15. Rome IV: Functional Constipation

16. Epidemiology and Burden of IBS and CIC

17. Barriers to Patient Care

19. Recurrent Abdominal Pain with Disordered Bowel Habits

20. History and Physical Examination for Lower GI Symptoms

21. Alarm Features for Organic Disorders

22. Recurrent Abdominal Pain with Disordered Bowel Habits

23. Diagnostic Testing for Suspected IBS, by Subtype

24. Blood-Based Biomarker for IBS-D: Comparisons of Anti-CdtB and Anti-Vinculin Antibodies Between IBS and IBD, Celiac and Controls

25. Increased Colonic Bile Acid Exposure in IBS 75SeHCAT Values—Rome II Subgroups

26. Increased Bile Acid Synthesis in IBS-D

27. Recurrent Abdominal Pain with Disordered Bowel Habits

28. Diagnosis of IBS in Primary Care Positive Strategy = Strategy of Exclusion

30. Management of Patients With IBS

31. Graded Approach to Treatment of IBS

32. Dietary and Lifestyle Considerations

33. FODMAPs: Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols

34. Fiber (Bulking) Therapy for IBS

35. Probiotics

36. Medical Therapy Considerations for IBS (Non-FDA Approved)

37. FDA-Approved Therapies for IBS

38. FDA-Approved Pharmacologic Options for CIC

39. Lubiprostone

40. Linaclotide

41. Plecanatide

42. Alosetron

43. Alosetron: FDA Indication

44. Prescribing Recommendations for Alosetron

45. Eluxadoline

46. Rifaximin

49. Knowledge Question

50. Knowledge Question

51. Knowledge Question

52. Conclusions and Q&A